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“Very” Very Late Stent Thrombosis: Acute Myocardial Infarction From Drug Eluting
Stent Thrombosis Occurring Greater Than 5 Years Post-Implantation
Antony G. Kaliyadan, Henry Siu, David Fischman, Nicholas Ruggiero, II, Babu Jasti,
Paul Walinsky, David Ogilby, Michael Savage
Thomas Jefferson University Hospital, Philadelphia, PA
Background: A serious long-term complication of drug-eluting stents (DES) is the
occurrence of very late stent thrombosis (VLST) beyond one year after implantation.
While VLST has been observed at least 3 to 5 years following the initial procedure, it
remains unknown whether DES thrombosis is a ﬁnite phenomenon which abates over
time or is a risk that persists indeﬁnitely.
Methods: A retrospective chart and angiographic review was performed to identify a
series of patients who presented to our institution with acute myocardial infarction
(MI) due to “very”, very late stent thrombosis (VVLST), deﬁned as stent thrombosis
occurring more than 5 years after DES implantation.
Results: The study group consisted of 6 patients (5 men and 1 woman), aged 32 to
70 years, who had angiographically conﬁrmed deﬁnite VVLST. Five of the patients
were active smokers and 3 were diabetic. Interval between stent implantation and
VVLST ranged from 5.6 to 7.0 years. The DES was sirolimus-eluting in 3 patients
and paclitaxel-eluting in 3 patients. None of the patients were taking clopidogrel at
the time of VVLST. The interval between clopidogrel discontinuation and VVLST
was 1 week in 2 patients, 3-6 months in 2 patients, and greater than 5 years in 2
patients. Only 2 patients were taking chronic aspirin therapy. Therefore, 4 of the 6
patients were on no antiplatelet therapy prior to VVLST. The clinical presentation
of VVLST was an acute MI in all patients, with ST segment elevation in 5 of the 6.
All patients were treated successfully by emergent repeat percutaneous coronary
intervention.
Conclusion: Risk of stent thrombosis persists beyond 5 years after implantation of
ﬁrst generation DES. These sobering ﬁndings underscore the need for clinical vigi-
lance in these patients and corroborate current PCI guidelines which recommend
continuing at least aspirin indeﬁnitely after DES.A
g
e
(y
ea
rs
)G
en
de
rM
on
th
s
B
et
w
ee
n
In
it
ia
l
D
E
S
an
d
V
V
LS
TTy
pe
of
D
E
SD
E
S
to
tr
ea
t
B
M
S
re
st
en
os
isC
lin
ic
al
P
re
se
nt
at
io
n
of
V
V
LS
TLe
si
on
Lo
ca
ti
onTI
M
I
Fl
ow
G
ra
deO
ff
A
sp
ir
in
[i
f
ye
s,
#
da
ys
]O
ff
C
lo
pi
do
g
re
l
[i
f
ye
s,
#
da
ys
]M
ed
ic
at
io
n
N
on
-c
om
pl
ia
nc
eH
TN D
M H
LB
M
I
(k
g
/
m
2
)S
m
ok
in
g
S
ta
tu
s70 Male 76 SES Yes NSTEMI OM1 0 Yes [730] Yes
[1,825]Yes No No Yes 23 Prior32 Male 84 SES No STEMI LAD 0 Yes [7] Yes, [7] Yes Yes Yes Yes 58 Active54 Male 68 PES No STEMI RCA 0 No Yes [180] No Yes No Yes 29 Active48 Female 67 SES No STEMI RCA 0 No Yes [90] No No No Yes 33 Active61 Male 77 PES No STEMI LAD 0 Yes
[1,825]Yes
[1,825]Yes Yes Yes Yes 23 Active63 Male 67 PES Yes STEMI LCx 0 Yes [7] Yes [7] No Yes Yes Yes 46 ActiveCRT-113
Post-procedural Hypotension After Primary Percutaneous Coronary Intervention in
ST-Elevation Myocardial Infarction
Jee Eun Kwon, Sang-Wook Kim, Wang-Soo Lee, Joon Hwa Hong, Sharath Kumar,
Eun Young Kim, Kwang Je Lee, Chee Jeong Kim, Dai Yun Cho, Tae Ho Kim
Chung-Ang University Hospital, Seoul, Korea, Republic of
Background: The clinical signiﬁcance of post-procedural hypotension has not been
evaluated in patients with ST elevation myocardial infarction (STEMI) after successful
primary percutaneous coronary intervention (PCI).Methods: Total of 236pts with STEMI who underwent primary PCI were reviewed.
Pts who presented with cardiogenic shock before or during PCI were excluded.
Echocardiography was done within 48hrs. All pts underwent VH-IVUS imaging of
culprit lesion.
Results: Among 236pts, 54pts presented with post-procedural hypotension after
successful primary PCI without any deﬁnite cause. Pt age was 62  8 yrs in post-PCI
hypotensive STEMI vs 58  13 in normotensive STEMI (p¼0.048). The incidence
of hypertension was 41% (21/54) in post-PCI hypotensive STEMI vs 54% (98/182) in
normotensive STEMI (p¼0.105). Peak troponin-I and CK-MB were similar, and
Thrombolysis in myocardial infarction (TIMI) grade before PCI was lower in hypo-
tensive group. However, door to balloon and symptom to balloon time were longer in
hypotensive group. Ejection fraction was lower and left ventricular end-systolic
dimension was larger in hypotensive group. Minimal lumen area (MLA) was smaller
and maximal necrotic core (%) was larger in post-PCI hypotensive STEMI, but the
incidence of VH-TCFA was similar (56% vs 42%, p¼0.505). By logistic multivariate
regression analysis, the most important independent predictors of post-procedural
hypotension were longer symptom to balloon time (OR 1.012, p¼0.0093) and percent
maximal necrotic core (OR 1.244, p¼0.018). However, there were no signiﬁcant
differences in the 30days and 1yr MACCE of these two group.
Conclusion: Post-procedural hypotension after successful primary PCI was predicted
by delayed reperfusion time and prominent necrotic core of culprit lesion, although it
results in no difference of patient’s outcome.post-PCI hypotensive
STEM (n¼54)
post-PCI normotensive
STEMI (n¼182) p-value
Peak CK-MB 275.08  209.38 248.49  228.31 0.536
Peak Troponin I 314.92  274.83 298.78  405.98 0.823
Door to balloon time 100  75.36 61.21  35.96 0.004
Sx to balloon time 352.70  295.35 149.37  75.63 <0.0001
TIMI grade (0/1/2/3) 42/4/8/0 83/31/68/0 0.004EF (%) 43.17  9.66 52.82  10.56 <0.0001
Lesion length (mm) 25.44  9.14 20.92  8.76 0.009
Distal reference lumen area (mm2) 2.99  0.42 3.19  0.47 0.026
Vessel area (mm2) 12.20  4.61 12.54  5.84 0.788
Lumen area (mm2) (MLA site) 2.80  0.82 3.38  2.18 0.048
Plaque area (mm2) (MLA site) 12.82  4.78 11.94  5.50 0.464
Remodeling index (max. NC site) 1.41  0.61 1.27  0.34 0.279
Average ﬁbrotic area (%) 59.77  14.61 63.11  15.44 0.337
Average ﬁbrofatty area (%) 14.14 14.67 11.45  7.64 0.379
Average NC area (%) 19.21  13.63 18.25  12.26 0.739
Average dense calcium area (%) 6.91  9.53 7.18  7.91 0.888
% Fibrotic area (max. NC site) 50.75  13.47 63.11  15.44 <0.0001
% Fibrofatty area (max. NC site) 5.65  6.58 11.45  7.64 <0.0001
% Necrotic core area (max. NC site) 33.50  14.84 18.25  12.26 <0.0001
% Dense calcium area (max. NC site) 10.09  7.41 7.18  7.91 0.102CRT-114
Addition of Eptifibatide to Bivalirudin During St-Elevation Myocardial Infarction: Role
for Combination Therapy?
Nevin Baker, Orlando Escarcega, Michael Lipinski, Marco Magalhaes, Sa’ar Minha,
Joshua Loh, Lakshmana Pendyala, Al Fazir Omar, Hideaki Ota, Augusto Pichard,
Lowell Satler, William O. Suddath, Rebecca Torguson, Ron Waksman
MedStar Heart Institute, Washington, DC
Background: Patients presenting with ST-elevation myocardial infarction (STEMI)
represent a high risk group for in-hospital adverse events. The value of eptiﬁbatide in
addition to bivalirudin in this population for prevention of such events has not been
determined.
Methods: 1,849 STEMI patients underwent primary percutaneous coronary inter-
vention; 1,639 received bivalirudin monotherapy compared with 210 who received
bivalirudin plus provisional eptiﬁbatide. Primary endpoint was a composite of in-
hospital death, Q-wave MI, or acute stent thrombosis; adjusted for group differences.
Safety was assessed by the occurrence of thrombolysis in myocardial infarction (TIMI)
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Database Registry (NCDR) bleeding risk score to evaluate independent risk.
Results: Signiﬁcant procedure related differences exist between groups (Table 1),
while in hospital adverse events were similar (OR: 0.12; 95% CI, 0.90 - 2.96). No
difference in TIMI major bleeding was seen (3.9% vs. 6%; p ¼ 0.20). Eptiﬁbatide
modestly increased the bleeding risk (OR: 1.64; 95% CI, 1.01 - 2.67, p ¼ 0.045),
however, it did not improve the NCDR bleeding risk models’ ability to predict
events.
Conclusion: Use of combination therapy reﬂects a high risk STEMI population.
Despite this, the risk of in-hospital adverse events was not different between patients
receiving bivalirudin plus eptiﬁbatide vs. bivalirudin monotherapy. Likewise, combi-
nation therapy did not increase rates of major bleeding. Therefore, the use of eptiﬁ-
batide should be considered in the higher risk STEMI population.CRT-115
In the Current Era of ST Elevation Myocardial Infarction Treatment, What Patients Are
Not Reperfused? - An Observational Analysis
Laurna McGovern,1 Thomas J. Kiernan2
1University College Cork, Cork, Ireland; 2Limerick University Hospital, Limerick, Ireland
Background: The current treatment of ST segment elevation myocardial infarction
(STEMI) is mechanical reperfusion by Primary Percutaneous Coronary Intervention
(PPCI) or systemic thrombolysis. Several factors are related to non-reperfusion, with
advanced age being particularly signiﬁcant. At present, no study has examined the
presentation and characteristics of the non-reperfused patient in Ireland. Further study
is clearly needed in this area, especially as the older demographic of the population
increases.
Objective: To deﬁne, understand and critically evaluate STEMI patients who do not
receive reperfusion therapy.
Methods: The Coronary Heart Attack Ireland Register (CHAIR) was used to
identify STEMI patients who did not receive reperfusion therapy between January 1st
2007 and December 31st 2011. A retrospective review of patient charts was performed
at Cork University Hospital, Mercy University Hospital, South Inﬁrmary Victoria
University Hospital and Mallow General Hospital. The contribution of non-reper-
fusion to patient mortality was also examined in terms of 30-day mortality and 1-year
mortality post STEMI.
Results: 77 cases were included. Results indicate that most were female (n¼47, 61%)
with a median age of 80.39 years. 54.5% (n¼42) had a past medical history of coronary
heart disease with hypertension being the main risk factor (n¼43, 55.8%). 49% (n¼38)
were considered independent in terms of ADLs. Patient mortality at 30 days post
STEMI was 55.8%. This increased to 61% at 1 year.
Conclusion: As the older demographic in our population increases, this patient cohort
will become particularly signiﬁcant. Mortality among these patients is high yet a sig-
niﬁcant number were considered independent in terms of ADLs. Prospective evalu-
ation of this patient cohort needs to take place to monitor the effect of the introduction
of the PPCI National Strategy in Ireland in 2012. Internationally, larger studies are
needed to determine the role of social factors as predictors of non-reperfusion.CRT-116
Predictors of Inappropriate Activation of the Cardiac Catheterization Laboratory for
Code STEMI
Tiffany Wang, Gaurav Sharma, Henry Chu, David M. Shavelle
University of Southern California, Los Angeles, CA
Background: Patients presenting with ST elevation myocardial infarction (STEMI)
beneﬁt from primary percutaneous coronary intervention (PCI) if performed in a
timely manner. Inappropriate activation (IA) of the cardiac catheterization laboratory
is associated with signiﬁcant time and ﬁnancial costs. Patient level predictors of IA
have not been well-characterized. The objective of this study was to determine pre-
dictors of IA in patients activated for code STEMI.
Methods: We retrospectively analyzed a cohort of 396 consecutive patients who were
activated for code STEMI from January 2009 through April 2011 at a large, urban
teaching hospital. Those who underwent emergent coronary angiography (with or without
PCI) were categorized as having appropriate activation (n¼228). Patients for whom code
STEMI activation was subsequently cancelled and did not undergo emergent coronary
angiography were categorized as inappropriate activation (n¼168). Both groups were
compared and predictors for IA were determined using multivariate logistic regression
analysis.
Results: IA occurred in 42% of patients activated for code STEMI. Mean age, gender
distribution, and history of prior myocardial infarction were similar between the
groups. Body mass index < 18.5, use of self-transport to the emergency department,
initial complaint, recent cocaine use, history of congestive heart failure, and history of
atrial ﬁbrillation were signiﬁcantly between the two groups. Independent predictors for
IA included age  35 years (odds ratio [OR], 4.85; 95% CI, 1.18-19.96; p¼0.03),
body mass index <18.5 (OR, 15.91; 95% CI, 5.38-47.07; p<0.0001), absence of both
chest pain and shortness of breath at presentation (OR, 3.21; 95% CI, 1.79-5.76;
p<0.0001), recent cocaine use (OR, 5.01; 95% CI, 1.19-10.12; p¼0.02), history of
congestive heart failure (OR, 3.59; 95% CI, 1.58-8.13; p¼0.002), and history of atrial
ﬁbrillation (OR, 3.47; 95% CI, 1.19-10.12; p¼0.02).
Conclusions: Multiple patient-level characteristics were associated with IA of the
cardiac catheterization laboratory. Younger age, absence of both chest pain and
shortness of breath, recent cocaine use, and history of heart failure and atrial ﬁbrillation
were independent predictors of IA.
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Hispanic Patients Undergoing Primary PCI within Los Angeles County STEMI Receiving
System
Eric Bansal, Takeshi Ozunaki, Han Tun, David Shavelle
University of Southern California, Los Angeles, CA
Background:Hispanics are one of the largest growing ethnic minorities in the United
States but have been under represented in contemporary cardiovascular trials. Infor-
mation regarding Hispanic patients treated with Primary PCI within a regional
STEMI system of care has not been previously reported.
Methods: The Los Angeles County Emergency Medical System (EMS) STEMI
Receiving Center (SRC) Database was queried from January 2007 to December 2011
to identify all patients with a pre-hospital ECG showing STEMI. Eight thousand,
eight hundred and thirty-seven patients were included; 1,737 (19.7%) were Hispanic
and 4,637 (52.5%) were non-Hispanic whites. Hispanic and non-Hispanic whites
undergoing primary PCI were compared based upon demographics, treatment time
intervals and in-hospital clinical outcome.
Results: Hispanic patients were younger compared to non-Hispanic whites, 62.8 vs 67.5
years, p<0.0001, respectively. Treatment times including medical contact to door time (21
 12.9 vs 20.7 12.2mins, p¼ 0.43) and door to balloon time (63.1 31.7 vs 63.9 33.1
mins, p¼ 0.20) were similar between the Hispanic and non-Hispanic whites, respectively.
Hispanic patients achieved a higher rate of TIMI 3 ﬂow in the infarct related artery
compared to non-Hispanic whites, 86.7% vs 83.7%, p ¼ 0.04, respectively. The rate of
vascular complications, need for emergent coronary artery bypass surgery, occurrence of
stroke, length of hospital stay and in-hospital mortality were similar between the groups
(Table).
